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Globally, ~71 million people are viraemic for hepatitis C virus 
(HCV) infection, with 10.2 million (14%) residing in sub-Saharan 
Africa.[1] The prevalence of HCV in South Africa (SA) is <1%, with 
modelled data suggesting ~600 000 infected.[2] Despite typical HCV 
transmission risks being present in SA, such as people who inject 
drugs (PWID), pre-1992 blood or blood products (before universal 
HCV screening was introduced into blood services), parenteral 
injuries in healthcare workers and traditional practices such as 
scarification, HCV epidemiology is incompletely characterised. 
Historically, blood transfusion service HCV incidence, as a marker of 
the general population in SA, is low at 0.03 - 0.1%.[3,4] Unsurprisingly, 
recent data from key populations in SA demonstrate a high prevalence 
of HCV and HIV-HCV co-infection.[5] HCV prevalence studies 
in men who have sex with men (MSM) have demonstrated rates 
of 6%, with genotype (GT) 1a and 3a the predominant genotypes 
identified. [6] Interestingly, to date no GT5a, an HCV genotype unique 
to SA, has been identified in any of the key population studies in 
SA. Local key population data align with global epidemiology as the 
current major drivers of ongoing HCV infection.[7] Key population 
patients tend to be younger, the median age being 29 years in SA, 
whereas the other HCV prevalence peak comprised people invariably 
>50  years of age.[5,6,8] In recent data from Cape Town looking at a 
general HCV patient cohort accessing treatment, 26% of patients had 
no identifiable risk factor, possibly pointing towards other parenteral 
exposure, e.g. through traditional or unsafe medical practices, as a 
likely means of transmission.[9] Rwandan data also identified that, in 
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Background. The epidemiology of hepatitis C virus (HCV) in the general population of South Africa (SA) is incompletely understood. 
A high HCV prevalence in key populations is known, but data are limited in terms of a broader understanding of transmission risks in our 
general population.
Objectives. To investigate a patient cohort with HCV infection clustering in a rural SA town, in order to identify possible HCV transmission 
risks, virological characteristics, phylogenetic data and treatment outcomes.
Methods. A cluster of patients with positive HCV serology, previously identified from laboratory records, were contacted by a local district 
hospital and offered confirmatory testing for HCV viraemia where needed. Those with confirmed HCV RNA were invited to a local hospital 
visit, where relevant demographic information was recorded, clinical assessment performed and a confidential questionnaire administered. 
HCV population-based sequencing was performed on HCV NS3/4A, NS5A and NS5B using polymerase chain reaction-specific or M13 
universal primers, and sequences were aligned using BioEdit 7.2.5. Phylogenetic trees were constructed. Clinical assessments included liver 
fibrosis determination with FibroScan (cut-off ≥12.5 kPa = F4). Patients were offered treatment, and sustained virological response (SVR) was 
confirmed by undetectable HCV RNA at least 12 weeks after the end of treatment.
Results. Twenty-one patients, all from the same town, median (interquartile range (IQR)) age 64 (59 - 70) years, 57% female, were evaluated. 
Of these, 24% (n=5) were HIV co-infected, stable on antiretrovirals. The median (IQR) alanine aminotransferase level was 51 (31 - 89) U/L, 
with fibrosis distribution including 29% F1, 29% F2, 9% F3 and 33% F4 METAVIR fibrosis. Virologically, two genotypes were observed: 62% 
(n=13) genotype (GT) 1b and 38% (n=8) GT5a. No patient had ever used injecting drugs, 14% (n=3) had received blood products before 1992, 
and 9.5% (n=2) had undergone traditional healer-administered scarification. All (n=21) reported attendance at a single primary care clinic 
in the past, with most (n=20) recalling having received parenteral therapies at the clinic. Phylogenetic analysis of the HCV NS5A and NS5B 
regions confirmed GT1b and GT5a genotypes and formed two separate clusters within their respective genotypes, suggesting a common source 
for each genotype infection. Most patients received treatment with sofosbuvir/daclatasvir, 1 was treated with sofosbuvir/velpatasvir, and 1 was 
re-treated with sofosbuvir/velpatasvir/voxilaprevir. Per protocol SVR was 95%, with the non-SVR patient successfully re-treated.
Conclusions. Data from a rural town cluster of patients suggest parenteral medical exposure as the probable common source of hepatitis C 
transmission risk. The cohort was of older age with a significant number having advanced fibrosis or cirrhosis, suggesting HCV acquisition in 
the distant past. Using a simplified care approach, treatment outcomes were very good.
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addition to scarification or traditional healer operations, healthcare 
interventions were associated with an increased likelihood of HIV 
or HCV infection.[10] Healthcare-acquired HCV infection accounts 
for a significant portion of the infections in highly HCV-prevalent 
countries such as Egypt and Pakistan.[11] However, data to suggest this 
as a mode of HCV transmission in SA are lacking.
Objectives
A clinical observation of an unusual number of patients, all emanating 
from a single SA rural town and testing positive for hepatitis C, 
warranted further investigation. Additionally, since 2015, given the 
evolution of hepatitis C therapy to the highly effective, well-tolerated 
and all-oral direct-acting antiviral (DAA) therapy, the prospect 
of managing these patients efficiently existed.[12] The patients also 
provided an opportunity for proper evaluation and treatment, to 
better understand their transmission risk and hence guide further 
intervention measures and policy development. For patients previously 
identified, previous pegylated interferon and ribavirin-based therapy 
was unavailable. The newer DAA therapy was not yet widely available 
and required South African Health Products Regulatory Authority 
(SAHPRA) named patient approval via a section 21 certificate.
Methods
A Port Elizabeth-based tertiary hospital specialist clinic observed 
a pattern of referral of patients with HCV infection. The patients 
clustered from a defined geographical area and town and were not 
characteristically from recognised key populations with a high HCV 
prevalence. To better understand this observation, apart from already 
known patients, National Health Laboratory Service records were 
accessed to identify patients who screened positive for HCV between 
January 2015 and January 2018 from the region in question. Contact 
tracing was undertaken to find those in whom hepatitis C viraemia 
had not been undertaken after screening HCV-seropositive. Hepatitis 
C screening had been performed with a laboratory-based anti-HCV 
antibody test (ARCHITECT I or II; Abbott Diagnostics, USA). 
Confirmation of HCV viraemia was performed using either Cobas 
Amplicor (Roche, Switzerland) or HCV Xpert (Cepheid, USA), as per 
standard diagnostic protocol. Where HCV viraemia had not yet been 
performed, patient contact tracing was done via a local hospital and 
patients were invited back.
The specialist clinic looked for mechanisms to better understand 
the observed clustering of HCV patients and sought access to care. 
In collaboration, the pan-genotypic DAA therapy, sofosbuvir and 
daclatasvir, donated by Médecins Sans Frontières, South Africa, to the 
University of Cape Town and Groote Schuur Hospital (UCT/GSH) 
Liver Clinic, was provided to enhance access to care for the HCV-
infected patients.
Clinicians from the specialist clinic in Port Elizabeth, in collaboration 
with a hepatologist from the UCT/GSH Liver Clinic in Cape Town, 
initiated a treatment intervention and patient evaluation. A total of 
67 patients who screened HCV-positive were identified from searching 
laboratory records. Of these, 18 could be traced; 13 patients were alive, 
and 5 were confirmed deceased with cause of death unknown. Of the 
13, most (12/13) were confirmed to be HCV viraemic. The remaining 
49 patients were untraceable. During the process, an additional 
9 patients, all from the same region (and not part of the initial 67), were 
identified. Patients were seen and evaluated either in their regional 
hospital (through two outreach visits) or in the specialist clinic.
Apart from the standard consent provided for a SAHPRA section 
21 certificate, patients were also requested to give consent (in their 
language of choice) prior to clinical evaluation, as an extensive 
standardised history of possible hepatitis C transmission risks was 
taken and documented. All patients’ relevant demographic, serological 
and virological data were captured. Patients were screened for HIV (if 
not known to be HIV-positive) and hepatitis B surface antigen (HBsAg; 
Roche Diagnostics, Switzerland). To be eligible for DAA therapy, 
HIV-infected patients were required to be stable on antiretroviral 
therapy with a suppressed HIV viral load. As a routine, all patients had 
baseline renal and liver function tests and hepatitis C viral sequencing 
performed using standard population-based Sanger sequencing to 
determine genotype and to construct phylogenetic trees. The NS3/4A, 
NS5A and NS5B polymerase chain reaction (PCR) products were 
directly sequenced using PCR-specific or M13 universal primers with 
the BigDye terminator cycle sequencing kit (Applied Biosystems, 
USA). Sequences were aligned using BioEdit 7.2.5[13] and phylogenetic 
trees were constructed in MEGA 6 (USA).[14]
Point-of-care liver fibrosis assessment was performed using vibration-
controlled transient elastography (FibroScan; Echosens, France), and 
patients were classified as having F0, F1, F2, F3 or F4 fibrosis according 
to the METAVIR system.[15] A FibroScan liver stiffness measurement 
of ≥12.5 kPa was used to define F4 fibrosis. Cirrhosis was classified 
according to the Child-Turcotte-Pugh system.[16]
Patients were treated with a combination of sofosbuvir and 
daclatasvir for 12 weeks. In those with cirrhosis, ribavirin 400 mg 
twice daily was added, or for those likely to be intolerant of ribavirin, 
treatment was extended to 24 weeks. In patients with predicted drug-
drug interactions with daclatasvir, dose adjustment was made for the 
duration of therapy.
A sustained virological response (SVR) was defined as a patient 
being PCR-negative for hepatitis C RNA using a sensitive HCV viral 
load analysis at least 12 weeks after the end of treatment. As per 
standard of care, patients failing to achieve SVR would be evaluated 
for re-treatment based on hepatitis C sequencing and determination of 
their HCV resistance-associated substitution analysis.
Ethics approval
The study was approved by the University of Cape Town Human 
Research Ethics Committee (ref. no. 624/2020).
Statistical analysis
All values are expressed as medians and interquartile ranges 
(IQRs) for continuous variables. Baseline and on-treatment data 
are summarised using standard descriptive characteristics. Where 
appropriate, differences between qualitative parameters were explored 
using the Wilcoxon rank-sum test. Statistical analysis was performed 
using MedCalc v19.5.3 (MedCalc Software, Belgium).
Results
A total of 21 patients were evaluated and treated, of whom 12 (57%) 
were female. Table 1 shows the baseline demographic data. The median 
(IQR) age was 64 (59 - 70) years, with no significant difference between 
women and men (64 (62 - 70) v. 59 (55 - 70) years, respectively; p=0.35). 
HIV co-infection was present in 5 patients (24%), all on antiretroviral 
therapy and virally suppressed. Although the number of patients is 
small, HIV-positive patients were younger than HIV-negative patients 
(median 65 v. 61 years; p=0.05). Overall, only two HCV genotypes 
were observed, 1b and 5a, with most (n=13; 62%) GT1b-infected. 
Baseline liver fibrosis assessment yielded 42% with advanced fibrosis 
or established cirrhosis; all but 1 of those with cirrhosis had Child-
Turcotte-Pugh class A compensated cirrhosis. Median alanine and 
aspartate transaminase levels, at 51 U/L and 54  U/L, respectively 
(normal range 5 - 40 U/L), were elevated at baseline.
Table 2 depicts associated comorbidities as well as epidemiological 
factors likely to be associated with HCV acquisition risk from 
785       August 2021, Vol. 111, No. 8
RESEARCH
Table 1. Baseline demographics (N=21)
Age (years)
Median (IQR) 64 (59 - 70)
Male/female, median (IQR) 59 (55 - 70)/64 (62 - 70); p=0.35
Female gender, n (%) 12 (57)
Ethnicity, n (%)
Black 10 (48)
Mixed ancestry 11 (52)
HCV genotype distribution, n (%)
1b 13 (62)
5a 8 (38)
HCV RNA (log10 IU/mL), median (IQR) 5.8 (5.4 - 6.3)
HIV-positive, n (%)* 5 (24)






Laboratory parameters (at baseline)
ALT (U/L), median (IQR) 51 (31 - 82)
AST (U/L), median (IQR) 54 (36 - 66)
Platelet count (× 109/L) median (IQR) 164 (116 - 259)
IQR = interquartile range; HCV = hepatitis C virus; HBsAg = hepatitis B surface antigen; ALT = alanine transaminase; AST = aspartate transaminase; ART = antiretroviral therapy.
*All patients on ART and HIV virally suppressed.
†Determined by liver biopsy or vibration-controlled transient elastography (FibroScan).
‡Child-Pugh class A/B.
Table 2. Patient comorbidities and HCV epidemiological risk factors
Patient no. HCV GT Comorbidities Alcohol PWID Transfusion Tattoo Surgical history
Local clinic 
attendance
1 1b HPT, RA No No No No Nil Yes
2 1b HPT, asthma No No Yes No Surgery (CS), dental work Yes
3 1b HPT, gout, 
hypercholesterolaemia
Yes No No No Dental work Yes
4 1b HPT, epilepsy No No No No Nil Yes
5 1b Ulcerative colitis No No No No Nil Yes
6 1b HIV Yes No No No Nil Yes
7 1b HPT, stroke No No No No Surgery (TAH) No
8 1b Nil No No No No Nil Yes
9 1b HPT, DM No No No No Surgery (tonsillectomy) Yes
10 1b HPT, DM Yes No No No Surgery (CS) Yes
11 1b HPT, HIV Yes No No No Surgery (tendon repair) Yes
12 1b Nil Yes No Yes No Dental work Yes
13 1b HPT, DM No No No Yes None Yes
14 5a Nil No No No No Dental work Yes
15 5a RA No No No No Nil Yes
16 5a HPT, DM, HIV, 
cardiomyopathy
Yes No No No Surgery (CS) Yes
17 5a HPT, DM No No Yes Yes Surgery (CS, 
cholecystectomy)
Yes
18 5a HPT No No No No Nil Yes
19 5a HPT, DM, HIV, 
hypothyroidism
No No No No Surgery (CS, 
thyroidectomy)
Yes
20 5a HPT Yes No No No Dental work Yes
21 5a HIV Yes No No No Surgery (orthopaedic), 
dental work
Yes
HCV = hepatitis C virus; GT = genotype; HPT = hypertension; RA = rheumatoid arthritis; DM = diabetes mellitus; PWID = person who injects/ed drugs;  
Transfusion = blood or blood products; CS = caesarean section; Dental work = multiple teeth extractions and/or invasive dental work; TAH = total abdominal hysterectomy.
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individual patient interviews. Hypertension 
and diabetes were frequently observed. No 
patients reported current or previous use 
of injecting drugs. Three patients reported 
receiving blood transfusions prior to 1992, 
all women and associated with peripartum 
haemorrhage. Notably, 13 patients (62%) 
reported a range of surgical interventions (as 
tabulated) or dental work. Of significance, 
almost all patients (n=20/21) reported 
having attended the town’s local primary 
care clinic during the preceding decades, 
with all recalling having received parenteral 
therapies at the clinic.
Fig. 1 depicts the neighbour-joining 
phylo genetic tree of a concatenated sequence 
of the NS5A and NS5B regions of the 
HCV genome (1 015 base pairs), which 
was constructed using sequences from the 
study participants, other local sequences 
and reference sequences from the GenBank 
database. Patients were infected with either 
HCV GT1b or GT5a, and each formed 
a separate cluster within the respective 
genotypes. The clustering suggests a 
common source or mode of infection. In 
2  cases (patients 11 and 15), samples from 
two different collection dates were available 
and each patient pair grouped together on 
the phylogenetic tree, indicating a close 
genetic relationship between sequences, 
although there was greater diversity in 
patient 11’s samples from 2018 and 2019.
Table 3 reports the patient DAA therapy 
regimens and treatment outcomes. Most 
received sofosbuvir/daclatasvir, with 1 patient 
switched to sofosbuvir/velpatasvir after 
reporting gastrointestinal intolerance to 
daclatasvir after 1 week. No other significant 
adverse events were reported. Per protocol, 
95% (20/21) achieved an SVR. The patient 
in whom treatment failed was successfully 
retreated with 12 weeks of sofosbuvir/
velpatasvir/voxilaprevir.
Discussion
We report our experience from a modest 
patient cohort, all emanating from a defined 
town in a rural area of SA and infected 
with HCV. These are the first such data 
to be reported in SA, and have advanced 
our understanding of HCV epidemiology 
in our country. We have also incidentally 
demonstrated that a treatment intervention 
for HCV-infected patients in this community 
is feasible and possible at point of service.
Several factors emerge from this patient 
cohort. Firstly, the median age of 64 years 
is much older than recently reported 
heterogeneous SA HCV patient cohorts, 
of 52 and 47 years, respectively.[9,17] Also, 
knowing the natural history of chronic HCV 
infection with a progression time to cirrhosis 
of ~20 - 40 years, infection in this cohort is 
likely to have occurred many years before, 
given that 42% had advanced fibrosis or 
cirrhosis.[18] It must, however, be noted that 
co-factors such as alcohol use and HIV 
co-infection influence the natural history of 
HCV. A substantial proportion (24%) of our 
cohort were HIV co-infected. Nonetheless, 
co-infection is usually seen in patients with 
Figure 1. NS5A/NS5B concatenated phylogenetic tree – GT1b and 5a cohort patients are 
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Fig. 1. NS5A/NS5B concatenated phylogenetic tree. GT1B and GT5a cohort patients are highlighted in 
red, other local sequences in green, and reference sequences from GenBank in black. 
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shared transmission risks for HIV and HCV, such as people who 
inject drugs or MSM.[12] These shared transmission risk factors were 
not observed in our patient cohort, suggesting HIV infection possibly 
following previous HCV infection, through dissimilar transmission 
routes. Although HIV co-infected patients in this cohort were slightly 
younger, although not significantly, their median age of 61 years 
is considerably older than the median age of HIV-positive South 
Africans in the general population, where the prevalence peaks at 35 - 
39 years of age.[19] This finding further supports our contention that 
HCV acquisition in our cohort is likely to have occurred before their 
HIV infection and not through shared transmission routes.
Another pertinent finding is that the phylogenetic concatenated 
tree supports the probability that the two HCV genotypes observed 
each arise from a common source. SA is pan-genotypic for HCV, with 
numerous data supporting this and confirming the relative endemic 
nature of GT5a, with GT1 being equally prevalent.[20] Of the many 
sub-genotypes of GT1, GT1a and GT1b are most frequently observed 
in SA, with GT1b representing 38 - 70% of GT1 sub-genotypes, 
suggesting that the GT1b sub-genotype in our cohort is in keeping 
with local patterns.[9,20] GT5a has also not been detected in any key 
population studies to date – here GT1 and GT3a are prevalent.[5]
Reviewing the patients’ self-reported histories suggests a shared 
mode of HCV transmission. Most patients reported attending the 
local primary care clinic and receiving parenteral therapies at time 
points in their lives. Healthcare-associated HCV infection is well 
described, and our study suggests this as the possible shared route 
of transmission. To date, this has not been clearly documented in 
SA. As noted, the more frequent means of transmission such as 
PWID were absent in this cohort. Equally, blood services in SA have 
adopted universal HCV screening since 1992.[3] This had the effect 
of reducing this route of HCV transmission to almost zero in the 
general population.[21] Other risk factors, e.g. traditional practices 
such as scarification, were identified in some of our patients, but 
were not frequently reported. Even so, it would not explain the 
phylogenetic findings. Unsafe medical or injection practices and 
iatrogenic transmission, through inadequate infection control, are a 
key risk factor for HCV transmission in high-prevalence countries 
such as Egypt, India, Pakistan and other parts of Asia.[22-24] Our 
study suggests this transmission route to be the likely common risk 
transmission factor. Equally, it perhaps represents a historic route 
of HCV infection in SA, given the significant changes in infection 
control practice emerging in the 1990s consequent to HIV and other 
emerging pathogens. This too could further explain the older age of 
this patient cohort.
We would suggest that more extensive HCV testing is now 
justified in this community and should form part of an expanded 
viral hepatitis screening, prevention and treatment service. SA has 
a national strategic plan on viral hepatitis with guidance on the 
management of viral hepatitis, adopted in 2019. COVID-19, while 
having created many challenges for the health sector and attenuated 
many health policies, has demonstrated what can be achieved if 
resolve is present.[25]
An important aspect of our study was the delivery of care to HCV- 
infected patients in a rural town, at point of service, with conse quent 
good outcomes. Such simplified care models are achievable, with 
decentralised care being delivered by local practitioners with support 
being provided by leveraging on technology such as the viral hepatitis 
ECHO programme started at the University of Cape Town and 
Groote Schuur Hospital in 2019.[26]
Conclusions
We report a patient cohort with HCV infection, observed to cluster 
from a rural SA town. The pattern was investigated through directly 
assessing patients and linking them to care at their point of service 
in their community. Epidemiological supported by virological data 
suggest probable previous unsafe administration of parenteral 
therapies as the mode of HCV transmission. Treatment outcomes 
were good; however, our findings warrant a specific intervention 
Table 3. Direct-acting antiviral treatment, duration and outcome
Patient no. HCV GT Treatment Ribavirin Treatment duration (weeks) Treatment outcome
1 1b SOF/DCV No 12 SVR
2 1b SOF/DCV Yes 12 SVR
3 1b SOF/DCV No 12 SVR
4 1b SOF/DCV No 12 SVR
5 1b SOF/DCV No 12 SVR
6 1b SOF/DCV No 12 SVR
7 1b SOF/DCV No 12 SVR
8 1b SOF/DCV No 24 SVR
9 1b SOF/DCV No 24 SVR
10 1b SOF/DCV Yes 12 SVR
11 1b SOF/DCV No 12 Treatment failure
12 1b SOF/DCV No 12 SVR
13 1b SOF/DCV No 24 SVR
14 5a SOF/DCV No 12 SVR
15 5a SOF/DCV No 12 SVR
16 5a SOF/VEL No 12 SVR
17 5a SOF/DCV No 24 SVR
18 5a SOF/DCV Yes 12 SVR
19 5a SOF/DCV No 12 SVR
20 5a SOF/DCV No 12 SVR
21 5a SOF/DCV No 12 SVR
GT = genotype; SOF/DCV = sofosbuvir/daclatasvir; SOF/VEL = sofosbuvir/velpatasvir; SVR = sustained virological response, per protocol.
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in this broader community to screen, diagnose and treat identified 
HCV infection.
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